All articles by Pradeep Bairaboina
Pradeep Bairaboina
BioNTech secures UK government grant to boost R&D in innovative medicines
The initiative aligns with the UK government’s strategy to bolster its life sciences sector and foster innovation in medical science
Quoin Pharmaceuticals announces EMA grants Orphan Drug Designation for QRX003 for the treatment of Netherton Syndrome
The company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients
Regeneron to acquire 23andMe’s assets in $256m deal
Regeneron plans to acquire 23andMe’s Personal Genome Service, Total Health, and Research Services divisions, as well as its Biobank and related assets
US FDA approves Incyte’s Zynyz for advanced anal canal cancer treatment
The approval of Zynyz as a monotherapy was based on the POD1UM-202 study, which reported an objective response rate of 14% and a disease control rate of 49%
Sarepta’s Elevidys receives conditional approval in Japan for DMD
The approval is based on the efficacy and safety data from clinical studies, including long-term functional results from the global Phase 3 EMBARK study
US FDA accepts Regenxbio’s application for MPS II gene therapy
The application seeks accelerated approval for treating Mucopolysaccharidosis II (MPS II), commonly referred to as Hunter syndrome
Recipharm and PLG announce strategic partnership to accelerate development projects
The two companies will ensure customers receive comprehensive support from early-stage development to approval and market access
Daiichi Sankyo seeks approval for Enhertu in Japan for HER2 positive tumours
The New Drug Application focuses on treating adult patients with HER2 positive advanced or recurrent solid tumours that do not respond to or cannot tolerate existing standard treatments
Thermo Fisher to invest $2bn to strengthen US healthcare supply chain
The investment plan includes $1.5bn for expanding and upgrading US manufacturing facilities, along with $500m directed towards R&D focused on high-impact innovations
Granite Bio secures $100m funding to advance autoimmune disease treatments
The financing includes a $30m Series A round, led by founding investors Versant Ventures and Novartis Venture Fund, and a $70m Series B round, led by Forbion and Sanofi Ventures